Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 24

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 24
---
 pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the Audit Committee or by a designated member of the Audit Committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the Audit Committee will consider whether such services are consistent with the SEC’s rules on auditor independence. The Audit Committee will also consider whether the independent auditor is best positioned to provide the most effective and efficient service, for reasons such as its familiarity with the Company’s business, people, culture, accounting systems, risk profile and other factors, and whether the service might enhance the Company’s ability to manage or control risk or improve audit quality. All such factors will be considered as a whole, and no one factor should necessarily be determinative. On an annual basis, the Audit Committee reviews and generally pre-approves the services (and related fee levels or budgeted amounts) that may be provided by Ernst & Young LLP without first obtaining specific pre-approval from the Audit Committee. The Audit Committee may revise the list of general pre-approved services from time to time, based on subsequent determinations. All of the services provided by Ernst & Young LLP during 2024 and 2023 were pre-approved by the Audit Committee.

<div align='center'>14</div>

#### Executive Officers
The following table identifies our current executive officers:

| Name                           |     | Age |     | Position(s)                           |
| Carsten Brunn, Ph.D.(1)        |     |  54 |     | President and Chief Executive Officer |
| Blaine Davis(2)                |     |  51 |     | Chief Financial Officer               |
| Metin Kurtoglu, M.D., Ph.D.(3) |     |  46 |     | Chief Technology Officer              |
| Christopher Jewell, Ph.D.(4)   |     |  44 |     | Chief Scientific Officer              |
| Milos Miljkovic, M.D.(5)       |     |  41 |     | Chief Medical Officer                 |
| Emily English, Ph.D.(6)        |     |  45 |     | Chief Operations Officer              |

1 See biography on page 8 of this proxy statement.

2 Blaine Davis has served as our Chief Financial Officer since November 2022. Prior to joining the Company, Mr. Davis served as Chief Financial Officer at Protara